Lantheus LNTH NASDAQ · Healthcare · United States
$102.10 +0.00% +$0.00
Summary
77 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 104% a year over the last 3 years.
- Out of every 100 USD of revenue, 17 USD is left as net profit.
- It holds more cash than debt: $683.6M against $54.0M.
- It bought back its own shares for $300.0M in the last fiscal year, 4.5% of its market value.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 24.7 USD for 1 USD of yearly profit. Over the last five years it was 45.4 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 35% a year over 5 years. Over the last 3 years it grew by 18% a year. Earnings per share grew by 104% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 39 USD
- Research and development 14 USD
- Sales and administration 29 USD
- Taxes and other 1.3 USD
- Net profit 17 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 USD
Out of every 100 USD of revenue, 17 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 10
- Hold 9
- Sell 0
Today's price within the analysts' price targets
The average target of $102.65 is 0.5% above today's price. 53% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 33%
- PYLARIFY 22%
- Radiopharmaceutical Oncology 22%
- Total Precision Diagnostics 11%
- DEFINITY 7.3%
- Other 4.5%
By region
- UNITED STATES 95%
- Non-US 5.4%
Product brings in 33% of revenue. PYLARIFY grew fastest, by 118% a year.
Segments in detail